VolitionRx Limited develops epigenetics-based diagnostics through its Nucleosomics platform, which measures nucleosomes in blood and other bodily fluids. The company’s Nu.Q® product portfolio spans human diagnostics and monitoring for cancer, sepsis, trauma biomarker research and other disease areas, as well as veterinary oncology through Nu.Q® Vet assays.
VNRX news covers clinical publications and assay-development milestones, commercialization of Nu.Q® tests, veterinary cancer-test development, recombinant nucleosome products under rNuQ™, licensing and distribution activity, financial results, non-dilutive funding, equity financing and NYSE American listing-compliance matters. Volition’s research and development activities are centered in Belgium, with additional operations in the United States and London.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
VolitionRx Limited (NYSE AMERICAN: VNRX) is set to host a Capital Markets Day on May 11, 2023, at 2 p.m. Eastern Time, in a hybrid format at the New York Stock Exchange and via live webcast. The event will feature presentations by the executive team and recognized experts in the field, including Dr. Andy Retter and veterinary oncologists Professor Heather Wilson-Robles and Dr. Sue Ettinger. Topics will include the company's corporate strategy, Nu.Q® technology applications in sepsis, and veterinary diagnostics. A Q&A session will follow the presentations. Interested attendees can register for the event virtually or contact for in-person attendance. The event will also be webcasted, with presentations available on Volition's website post-event. VolitionRx focuses on cost-effective blood tests for diagnosing and monitoring diseases like cancer.